GlassScriptPhysician profile
Tuantu Doan Vu
NPI 1871520809
$6,005.74
in general payments reported to CMS, 2019-2025
27 companies · $1,383 in 2025
The $1,383 reported for 2025 was more than what 93% of Surgical providers received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $535 · 2022: $1,242 · 2023: $1,402 · 2024: $1,444 · 2025: $1,383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,213 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,213.27 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $1,188.27 | 2021-2025 | Opzelura, Iclusig |
| Abbvie INC. | $1,057.36 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $478.09 | 2021-2025 | |
| Ucb, INC. | $452.80 | 2022-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $392.12 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $390.51 | 2021-2025 | Blu-U, Ilumya |
| Leo Pharma INC. | $194.60 | 2022-2025 | Adbry |
| Galderma Laboratories, L.P. | $190.79 | 2021-2025 | Nemluvio, Aklief |
| Amgen INC. | $171.20 | 2021-2024 | Otezla |
| Lilly USA, LLC | $169.90 | 2021-2025 | Taltz, Ebglyss, Zepbound |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $164.92 | 2024-2025 | Siliq, Cabtreo, Jublia |
| Pfizer INC. | $149.44 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Janssen Biotech, INC. | $113.00 | 2021-2023 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $103.72 | 2022-2025 | Dupixent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $96.04 | 2023 | Shingrix |
| Arcutis Biotherapeutics, INC. | $93.59 | 2024-2025 | Zoryve |
| Boston Scientific Corporation | $83.18 | 2022 | |
| Allergan, INC. | $71.39 | 2022 | |
| Organogenesis INC. | $70.02 | 2025 | Cygnus Matrix, Via Matrix, Puraply Wound Matrix |
| Dermavant Sciences, INC. | $58.27 | 2024 | Vtama |
| Biofrontera INC. | $54.38 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Genzyme Corporation | $42.72 | 2022-2025 | |
| Strata Skin Sciences, INC. | $30.21 | 2024 | Xtrac |
| Epi Health, LLC | $28.31 | 2021-2022 | |
| Organon LLC | $21.68 | 2025 | Vtama |
| Botanix Sb INC | $14.23 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tuantu Doan Vu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.